NCT06859099
Long-term Safety and Efficacy Study of Riliprubart in Participants With CIDP
Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatmentSanofi
~300 participants
Updated 2026-07-13 on ClinicalTrials.gov
What's tested:Riliprubart Prefilled Pen (PFP)
At a glance
Recruiting sites
0 of 49 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study period
Measured over Up to End of Study (approx. 4 years)
Conditions
Where it's being run
49 sites across 30 statesChina8
France4
Germany3
Spain3
Quebec2
Reg Metropolitana de Santiago2
Czechia2
Milano2
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Number of participants having any AEs, SAEs, adverse events leading to treatment discontinuation, AESIs, and potentially clinically significant abnormalities (PCSAs) in safety laboratory tests, ECGs, and vital signs during the study periodUp to End of Study (approx. 4 years)
adverse events: AEs, serious adverse events: SAEs, adverse events of special interest: AESIs, electrocardiograms: ECGs